Q2 2019 EPS Estimates for Karyopharm Therapeutics Inc Increased by Analyst (KPTI)

Karyopharm Therapeutics Inc (NASDAQ:KPTI) – Jefferies Financial Group upped their Q2 2019 earnings per share estimates for shares of Karyopharm Therapeutics in a report issued on Monday, May 13th. Jefferies Financial Group analyst M. Raycroft now anticipates that the company will earn ($0.85) per share for the quarter, up from their prior forecast of ($0.95). Jefferies Financial Group also issued estimates for Karyopharm Therapeutics’ Q3 2019 earnings at ($0.83) EPS, Q4 2019 earnings at ($0.80) EPS, FY2019 earnings at ($3.57) EPS, FY2020 earnings at ($1.58) EPS, FY2021 earnings at ($1.46) EPS and FY2022 earnings at ($0.38) EPS.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, May 9th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.25). The company had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.75 million. Karyopharm Therapeutics had a negative return on equity of 119.66% and a negative net margin of 1,005.85%.

Other analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating on shares of Karyopharm Therapeutics in a research report on Wednesday, February 27th. Zacks Investment Research downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 15th. ValuEngine raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 27th. JPMorgan Chase & Co. downgraded shares of Karyopharm Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $21.00 to $7.00 in a research report on Friday, March 1st. Finally, Wedbush dropped their target price on shares of Karyopharm Therapeutics from $19.00 to $14.00 and set an “outperform” rating on the stock in a research report on Monday, February 25th. Four equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $17.75.

NASDAQ:KPTI opened at $4.64 on Wednesday. The company has a market cap of $262.93 million, a price-to-earnings ratio of -1.48 and a beta of 3.09. Karyopharm Therapeutics has a twelve month low of $3.92 and a twelve month high of $21.71. The company has a current ratio of 6.19, a quick ratio of 6.19 and a debt-to-equity ratio of 0.98.

In other news, major shareholder Ltd Chione sold 1,481,643 shares of the company’s stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $4.81, for a total value of $7,126,702.83. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 13.26% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in KPTI. Wells Fargo & Company MN boosted its holdings in shares of Karyopharm Therapeutics by 14.1% in the 3rd quarter. Wells Fargo & Company MN now owns 42,274 shares of the company’s stock valued at $720,000 after acquiring an additional 5,239 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Karyopharm Therapeutics by 2.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 218,594 shares of the company’s stock valued at $3,723,000 after purchasing an additional 4,576 shares during the period. MetLife Investment Advisors LLC lifted its stake in shares of Karyopharm Therapeutics by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 35,758 shares of the company’s stock valued at $609,000 after purchasing an additional 12,711 shares during the period. AQR Capital Management LLC lifted its stake in shares of Karyopharm Therapeutics by 60.6% in the 3rd quarter. AQR Capital Management LLC now owns 30,767 shares of the company’s stock valued at $524,000 after purchasing an additional 11,614 shares during the period. Finally, Teachers Advisors LLC lifted its stake in shares of Karyopharm Therapeutics by 1.4% in the 3rd quarter. Teachers Advisors LLC now owns 337,478 shares of the company’s stock valued at $5,747,000 after purchasing an additional 4,800 shares during the period. 86.46% of the stock is currently owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.

Further Reading: What is Put Option Volume?

Earnings History and Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.